LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Feasibility Study Supports Use of Immunomagnetic Approach to Study Circulating Cancer Cells

By LabMedica International staff writers
Posted on 01 Apr 2015
Print article
Image: In the immunomagnetic approach, circulating cancer cells are attracted by specific biomarkers to bind to an array of micromagnets for further analyses (Photo courtesy of Dartmouth College).
Image: In the immunomagnetic approach, circulating cancer cells are attracted by specific biomarkers to bind to an array of micromagnets for further analyses (Photo courtesy of Dartmouth College).
Cancer researchers have combined the strength of magnetic separation with the specificity of immunochemical biomarker recognition to demonstrate the feasibility of capturing and analyzing rare circulating cells from the blood stream of cancer patients.

Writing in the March 4, 2015, online edition of the journal Scientific Reports, investigators at Dartmouth College (NH, USA) described a two-dimensional micromagnet array that they used to characterize generation of the magnetic field and to quantify the impact of micromagnets on rare cell separation. In this paper, they presented a theoretical framework and technical approach to implement microscale magnetic immunoassay through modulating the local magnetic field towards enhanced capture and distribution of rare cancer cells.

"The concept is to use novel cell-machine interfaces, integrated sensing, actuation, and biomarker recognition functionalities to isolate these rare cells (one per billion hematologic cells) from whole blood to determine malignancy unambiguously," said senior author Dr. John X.J Zhang, professor of engineering at Dartmouth College. "We will base the quantitative assessment on multiple tumor markers. This project demonstrates that a relatively simple blood test may eventually be able to provide unambiguous information to doctors about particular cancers in individuals."

The investigators found that there was good agreement between their theory and results of experiments using a human colon cancer cell line (COLO205) as the capture targets.

Related Links:

Dartmouth College


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more